Amer M. Zeidan

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.253Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-0592

Top 60%

0.253DataRank

Top 60%4 citations

Xiaoyi Wang, Rong Wang, Jonathan N. Hofmann, Linda M. Liao, Amer M. Zeidan +3 more

Papers

Driven by 58 papers — median percentile 40. Top paper: “Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial”.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00494-0

N/A

4.0DataRank · unranked

193 citations

Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton +12 more

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Blood Advances(2020)10.1182/bloodadvances.2019000767

N/A

2.9DataRank · unranked

56 citations

Wendy Stock, Amer M. Zeidan, Ehab Atallah, James McCloskey, Leonard T. Heffner +11 more

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Leukemia(2022)10.1038/s41375-022-01724-9

N/A

0.926DataRank · unranked

28 citations

Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A. Sekeres, David P. Steensma, Uwe Platzbecker +44 more

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Annals of Hematology(2023)10.1007/s00277-023-05552-4

N/A

0.726DataRank · unranked

23 citations

Rory M. Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E. Roe +18 more

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Annals of Hematology(2022)10.1007/s00277-021-04734-2

N/A

0.685DataRank · unranked

95 citations

Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei +8 more

Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study

International Journal of Cancer(2020)10.1002/ijc.32853

N/A

0.638DataRank · unranked

14 citations

Xiaoyi Wang, Rong Wang, Jonathan N. Hofmann, Linda M. Liao, Amer M. Zeidan +3 more

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1966788

N/A

0.574DataRank · unranked

45 citations

Andriy Derkach, Lohith Gowda, Kamal Menghrajani, Susan DeWolf, Josel D. Ruiz +27 more

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Blood Advances(2022)10.1182/bloodadvances.2022008747

N/A

0.525DataRank · unranked

11 citations

Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie +45 more

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Blood Advances(2023)10.1182/bloodadvances.2023011308

N/A

0.483DataRank · unranked

24 citations

Mei‐Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly +64 more

Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.05.018

N/A

0.464DataRank · unranked

21 citations

Smith Giri, Rong Wang, Nikolai A. Podoltsev, Christina Williamson, Raajit K. Rampal +4 more

Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.70012

N/A

0.330DataRank · unranked

8 citations

Scott F. Huntington, Amer M. Zeidan, Jan Philipp Bewersdorf

PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0260

N/A

0.316DataRank · unranked

5 citations

Ka-Kui Chan, Sheng Liu, Jun Wan, Steven P. Angus, Steven D. Rhodes +10 more

Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-0592

Top 60%

0.253DataRank

Top 60%4 citations

Xiaoyi Wang, Rong Wang, Jonathan N. Hofmann, Linda M. Liao, Amer M. Zeidan +3 more

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.05.016

N/A

0DataRank · unranked

20 citations

Amar H. Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev +7 more

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

Cancer Management and Research(2021)10.2147/cmar.s240600

N/A

0DataRank · unranked

17 citations

Jan Philipp Bewersdorf, Amer M. Zeidan, Russell S. Lewis

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States

Blood Advances(2021)10.1182/bloodadvances.2021005642

N/A

0DataRank · unranked

12 citations

Stephanie Prozora, Nikolai A. Podoltsev, Rory M. Shallis, Scott F. Huntington, Natalia Neparidze +4 more

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

Oncotarget(2021)10.18632/oncotarget.27919

N/A

0DataRank · unranked

4 citations

Amer M. Zeidan, Jan Philipp Bewersdorf

Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.10.010

N/A

0DataRank · unranked

3 citations

Elizabeth Lyden, Utsav Joshi, Avantika Pyakuryal, Krishna Gundabolu, Amer M. Zeidan +4 more

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.01.003

N/A

0DataRank · unranked

1 citations

Jan Philipp Bewersdorf, David M. Swoboda, Wei Wei, Lohith Gowda, Thomas Prébet +10 more

Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7045

N/A

0DataRank · unranked

0 citations

Amar H. Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev +7 more

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood(2022)10.1182/blood.2022015832

N/A

0DataRank · unranked

36 citations

Pierre Fenaux, Marco Gobbi, Jiřı́ Mayer, Gail J. Roboz, Jürgen Krauter +21 more

CHIPing away the progression potential of CHIP: A new reality in the making

Blood Reviews(2022)10.1016/j.blre.2022.101001

N/A

0DataRank · unranked

21 citations

Amer M. Zeidan, Zhuoer Xie

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Leukemia(2022)10.1038/s41375-022-01738-3

N/A

0DataRank · unranked

21 citations

Mei‐Jie Zhang, Karen Chen, Hisham Abdel‐Azim, Muhammad Bilal Abid, Mahmoud Aljurf +47 more

TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Cancer(2022)10.1002/cncr.34535

N/A

0DataRank · unranked

17 citations

Naval Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker +5 more

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Blood(2022)10.1182/blood.2021014401

N/A

0DataRank · unranked

11 citations

Kishan Patel, George Goshua, Rory M. Shallis, Nikolai A. Podoltsev, Scott F. Huntington +2 more

How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines

Blood(2023)10.1182/blood.2022017808

N/A

0DataRank · unranked

47 citations

Christopher S. Hourigan, Amer M. Zeidan, Firas El Chaer

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Blood Reviews(2023)10.1016/j.blre.2023.101128

N/A

0DataRank · unranked

31 citations

Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami S. Komrokji, Mina L. Xu +43 more

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Blood Reviews(2023)10.1016/j.blre.2023.101072

N/A

0DataRank · unranked

18 citations

Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M. Brunner +37 more

PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

Journal of Clinical Investigation(2023)10.1172/jci164325

N/A

0DataRank · unranked

18 citations

Xue Han, Qianni Hu, Esten N. Vandsemb, Carly M. Fielder, Junshik Hong +21 more

Considerations for Drug Development in Myelodysplastic Syndromes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3348

N/A

0DataRank · unranked

12 citations

Nina Kim, Amy E. DeZern, Kelly J. Norsworthy, Jacqueline S. Garcia, R. Angelo de Claro +6 more

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood(2024)10.1182/blood.2024024756

N/A

0DataRank · unranked

50 citations

Rami S. Komrokji, Najla Al‐Ali, Alexandra Regelson, Susan Geyer, Anand Patel +39 more

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood Cancer Journal(2024)10.1038/s41408-024-01000-2

N/A

0DataRank · unranked

31 citations

Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Sacchi de Camargo Correia Guilherme, Aaron D. Goldberg +12 more

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Modern Pathology(2024)10.1016/j.modpat.2024.100615

N/A

0DataRank · unranked

12 citations

Savanah D. Gisriel, Amer M. Zeidan, John M. Bennett, Rafael Bejar, Jan Philipp Bewersdorf +48 more

Advancing drug development in myelodysplastic syndromes

Blood Advances(2024)10.1182/bloodadvances.2024014865

N/A

0DataRank · unranked

12 citations

Kathy L. McGraw, Lea Cunningham, Nina Kim, Emily Y. Jen, Katherine R. Calvo +17 more

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Blood Advances(2024)10.1182/bloodadvances.2024012858

N/A

0DataRank · unranked

12 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0719

N/A

0DataRank · unranked

5 citations

Wenhuo Hu, Ashwin Kishtagari, Bo Shen, Xiang Gao, Caroline M. Blackman +19 more

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

American Journal of Hematology(2024)10.1002/ajh.27366

N/A

0DataRank · unranked

9 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

Clinical Trials(2025)10.1177/17407745241304065

N/A

0DataRank · unranked

2 citations

Michael LeBlanc, Boris Freidlin, Rory M. Shallis, Amer M. Zeidan, David A. Sallman +4 more

Advances and Challenges in the Management of Myelodysplastic Syndromes

Cancers(2025)10.3390/cancers17152469

N/A

0DataRank · unranked

5 citations

Tariq Kewan, Amer M. Zeidan, Jessica M. Stempel

Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights

Blood Reviews(2025)10.1016/j.blre.2025.101301

N/A

0DataRank · unranked

2 citations

Yazan F. Madanat, Yasmin Abaza, Amer M. Zeidan, Alain Mina

Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis

Blood Advances(2025)10.1182/bloodadvances.2025017611

N/A

0DataRank · unranked

2 citations

Naira Link Woite, Benjamin Rolles, Jessica M. Stempel, Alain Mina, Lourdes Mendez +7 more

Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database

Annals of Hematology(2025)10.1007/s00277-025-06307-z

N/A

0DataRank · unranked

3 citations

Rong Wang, Alfred Ian Lee, Amer M. Zeidan, Xiaomei Ma, Nikolai A. Podoltsev +1 more

Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML

Blood Advances(2025)10.1182/bloodadvances.2025016532

N/A

0DataRank · unranked

1 citations

Kishan Patel, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez +8 more

Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib

Blood Neoplasia(2025)10.1016/j.bneo.2025.100159

N/A

0DataRank · unranked

0 citations

Jessica M. Stempel, Rory M. Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze +6 more

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

Cells(2020)10.3390/cells9102310

N/A

0DataRank · unranked

102 citations

Amer M. Zeidan, Jan Philipp Bewersdorf

Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States

Cancer(2026)10.1002/cncr.70415

N/A

0DataRank · unranked

0 citations

Rong Wang, Lourdes Mendez, Alain Mina, Luis E. Aguirre, Maximilian Stahl +4 more

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

Haematologica(2020)10.3324/haematol.2019.242826

N/A

0DataRank · unranked

99 citations

Smith Giri, Rong Wang, Robert T. Williams, Martin S. Tallman, Amer M. Zeidan +2 more

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

The Lancet Haematology(2020)10.1016/s2352-3026(20)30205-2

N/A

0DataRank · unranked

97 citations

Prajwal Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal +47 more

Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map

Blood Reviews(2020)10.1016/j.blre.2020.100706

N/A

0DataRank · unranked

85 citations

Rong Wang, Amy J. Davidoff, Xiaomei Ma, Nikolai A. Podoltsev, Amer M. Zeidan +1 more

Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis

Leukemia(2020)10.1038/s41375-020-01020-4

N/A

0DataRank · unranked

70 citations

Smith Giri, Rong Wang, Nikolai A. Podoltsev, Robert T. Williams, Martin S. Tallman +4 more

Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis

Transfusion(2020)10.1111/trf.15994

N/A

0DataRank · unranked

64 citations

Smith Giri, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl, Jan Philipp Bewersdorf

Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS‐CoV‐2 pandemic

American Journal of Hematology(2020)10.1002/ajh.25853

N/A

0DataRank · unranked

10 citations

Terra L. Lasho, Eric Padron, Kristen McCullough, Aref Al‐Kali, Ayalew Tefferi +6 more

Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?

Best Practice & Research Clinical Haematology(2020)10.1016/j.beha.2020.101222

N/A

0DataRank · unranked

10 citations

Amer M. Zeidan, Jan Philipp Bewersdorf

No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet?

The Lancet Haematology(2020)10.1016/s2352-3026(20)30114-9

N/A

0DataRank · unranked

0 citations

Alì Taher, Amer M. Zeidan, Jan Philipp Bewersdorf

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

The Lancet Haematology(2021)10.1016/s2352-3026(20)30429-4

N/A

0DataRank · unranked

360 citations

Neel S. Bhatt, Andrew St. Martin, Muhammad Bilal Abid, Jenni Bloomquist, Roy F. Chemaly +11 more

Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?

Best Practice & Research Clinical Haematology(2021)10.1016/j.beha.2021.101245

N/A

0DataRank · unranked

26 citations

Amer M. Zeidan, Jan Philipp Bewersdorf

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Cancers(2021)10.3390/cancers13071610

N/A

0DataRank · unranked

31 citations

Amer M. Zeidan, Jan Philipp Bewersdorf

Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.09.005

N/A

0DataRank · unranked

31 citations

Cecily Allen, Abu‐Sayeef Mirza, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev +6 more

Amer M. Zeidan

Indexed papers

Top data-sharing exemplar

Papers